Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of HT-6184 in Healthy Volunteers
NCT05447546Phase 1Completed
- Sponsor
- Halia Therapeutics
- Start
- Jun 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ofirnoflast in myelodysplastic syndromes (MDS) and Inflammatory Disorders (10 arms), sponsored by Halia Therapeutics. Primary endpoints: Incidence of adverse events up to 6 weeks, Incidence of abnormal laboratory test results up to 6 weeks and 1 more. Started Jun 2022; status: completed.
02
Drugs
ofirnoflast
03
Conditions
myelodysplastic syndromes (MDS)Inflammatory Disorders
Beyond the preview
Go deeper on NCT05447546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05447546.